-
-
-
-
-
-
-
Alkermes (ALKS) PT Raised to $54 at Needham
-
-
-
-
-
-
-
Alkermes publishes 56-week LYBALVI analysis on schizophrenia symptoms
-
-
-
-
-
-
-
Alkermes receives FDA breakthrough therapy designation for narcolepsy drug
-
-
-
-
-
-
-
BofA Securities Reiterates Neutral Rating on Alkermes (ALKS)
-
-
-
-
-
-
-
Stifel: 'ALKS Shares Should Get a Boost on CNTA Disclosure'
-
-
-
-
-
-
-
Alkermes (ALKS) PT Raised to $47 at RBC Capital
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
-
430,266 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

